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Abstract: Tumor-Associated Macrophages (TAM) are key components of the reactive 
stroma of tumors. In most, although not all cancers, their presence is associated with poor 
patient prognosis. In addition to releasing cytokines and growth factors for tumor and 
endothelial cells, a distinguished feature of TAM is their high-rate degradation of  
the extra-cellular matrix. This incessant stroma remodelling favours the release of  
matrix-bound growth factors and promotes tumor cell motility and invasion. In addition, 
TAM produce matrix proteins, some of which are typical of the neoplastic tissues. The 
gene expression profile of TAM isolated from human tumors reveals a matrix-related 
signature with the up-regulation of genes coding for different matrix proteins, as well as 
several proteolytic enzymes. Among ECM components are: osteopontin, osteoactivin, 
collagens and fibronectin, including also a truncated isoform of fibronectin termed 
migration stimulation factor. In addition to serve as structural proteins, these matrix 
components have key functions in the regulation of the vessel network, in the inductionof 
tumor cell motility and degradation of cellular debris. Among proteolytic enzymes  
are: matrix metalloproteases, cathepsins, lysosomal and ADAM proteases, and the  
urokinase-type plasminogen activator. The degrading activity of TAM, coupled to the 
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production of bio-active ECM proteins, co-operate to the build-up and maintenance of an 
inflammatory micro-environment which eventually promotes tumor progression. 
Keywords: Tumor-Associated Macrophages (TAM); extra-cellular matrix (ECM); stroma; 
proteases; MMPs; cancer; inflammation 
 
1. Introduction 
Mononuclear phagocytes are essential cells for wound healing and tumors can be described as  
wounds that never heal [1]. Macrophages are numerous in the stroma of experimental and human 
tumors and mediate important biological functions that profoundly affect tumor cell behaviour. By 
secreting a number of diverse chemoattractants, primary tumors recruit blood circulating monocytes; 
here they differentiate to Tumor-Associated Macrophages (TAM) primarily because of the presence of 
M-CSF produced by neoplastic cells. Conditioned by the local milieu (rich in IL-10, TGFβ and 
prostaglandins), they acquire immune-suppressive and pro-tumoral effector properties. TAM are key 
players in cancer-related inflammation; with their continual deposition and degradation of the extra-
cellular matrix (ECM) TAM actively contribute to the build-up the typical reactive micro-environment 
of tumors. 
The interstitial matrix is an intricate and highly dynamic network of fibres composed of 
glycosaminoglycan (GAG)-containing glycoproteins. Different types of fibrous collagen together with 
fibronectin, hyaluronan and proteoglycans confer mechanical strength, elasticity and a precise spatial 
organization to tissues. In addition, the extracellular basement membrane, a specialized form of sheet-
like ECM mainly composed by collagen IV and laminins, is very important to sustain the epithelial 
cell layer and maintain orientation of apicobasal polarity [2]. Besides structural support, the interstitial 
matrix and basement membranes are important to integrate complex signalling and to regulate cellular 
movement, proliferation and differentiation [3,4]. Furthermore, the ECM contains a wide range of 
growth factors that are bound in an inactive form to matricellular proteins, but can be rapidly released 
and activated in case of need, for example during tissue repair [5-7]. 
Neoplastic cells modify their stroma and vasculature through production and secretion of different 
growth factors and cytokines. The locally changed host microenvironment, in turn, regulates the 
proliferation and invasive behaviours of tumor cells. The tumoral ECM presents several different 
features compared to normal tissue ECM, not only for the presence of aberrantly expressed or 
modified structural proteins but also, and most importantly, because of the incessant remodelling 
operated by several proteolytic enzymes. ECM degradation has several important consequences: 
altered stiffness and composition of the ECM; fragmentation of basement membranes, which 
facilitates the motility and invasive ability of tumor cells; deregulated organization of the vessel 
network. All these processes, initially guided by tumor cells and gradually involving the contribution 
of host cells, lead to the construction of a reactive stroma where the cross-talk and signalling between 
the diverse cell types and ECM proteins is outside the normal control. Here we will review the role of 
tumor macrophages in neoplastic tissues, in particular their important contribution to the continuous 
remodelling of the tumor stroma. 
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2. Significance of Macrophages in Tumors 
Macrophages are versatile cells that are capable of displaying different functional activities, some of 
which are antagonistic; for instance they can be immuno-stimulatory or immuno-suppressive, and 
either promote or restrain inflammation [8,9]. This functional plasticity is regulated by local cues to 
which the macrophages respond. For instance during bacterial infections macrophages first orchestrate 
the acute inflammatory response and eliminate the invading pathogens; at later time points they 
transform into scavengers of tissue debris, and finally trigger the proliferative phase of healing by 
releasing a variety of growth factors and cytokines which recruit and activate fibroblasts and new 
vessels [10-15]. 
Macrophage heterogeneity has been simplified in the macrophage polarization concept where the 
two extreme phenotypes, the M1 and M2 macrophages, have distinct features. M1 or classically–activated 
macrophages are stimulated by bacterial products and Th1 cytokines (e.g., IFN); they are potent 
effectors that cope bacterial infections and may have cytotoxic activity towards transformed cells [16,17]. 
M2 or alternatively activated macrophages differentiate in micro-environments rich in Th2 cytokines 
(e.g., IL-4, IL-13); they have high scavenging activity, produce several growth factors that activate the 
process of tissue repair and suppress adaptive immune responses [18-20]. 
In established tumors, TAM resemble M2-like macrophages [21-23]. While M2-related activities 
are of extreme importance during wound healing to return to the homeostatic state, in the context of a 
growing tumor they may favour disease progression [16,17,21,24-27]. Indeed, neoplastic tissues show 
similarities to sites of tissue repair (Figure 1). 
TAM are poorly cytotoxic against neoplastic cells and, instead, have been shown to influence 
fundamental aspects of tumor biology. Among the well documented pro-tumor functions of TAM is 
the production of many growth factors for tumor cells and for the nascent blood and lymphatic vessels, 
which are essential for the neo-angiogenesis switch and tumor proliferation. These include for instance 
epidermal, fibroblast and vascular growth factors (EGF, FGF, VEGF) [25,28-30]. TAM are also a 
major source of proteolytic enzymes that degrade the extra-cellular matrix thus favouring the invasion 
of neoplastic cells [25,31]. They contribute to the evasion of tumors from immune control by producing 
immune-suppressive cytokines such as IL-10 and TGF-beta [25,32]. 
In line with the above evidence, high density of TAM has been significantly associated with poor 
prognosis in the majority of tumors [17,20,25,33]. Indeed, markers of macrophages or their products 
are present in the stroma-associated gene signature predicting clinical outcomes (see below). 
Some studies in human colorectal cancer, however, indicated that macrophages may have  
anti-tumor activity [34-36]. TAM localization appears of primary importance: the number of 
peritumoral macrophages, but not of those within the cancer stroma, was associated with improved 
disease-free survival. Peritumoral macrophages had higher expression of costimulatory molecules 
(CD80 and CD86) and were able to induce apoptosis in cancer cells by a Fas ligand-dependent 
mechanism [37,38]. It may be possible that by being less exposed to tumor-derived immune-suppressive 
cytokines outer macrophages are able to differentiate into cytotoxic effectors. 
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Figure 1. Comparison between wound healing and the reactive tumor microenvironment. 
Wound repair after tissue injury (a) is characterized by platelet aggregation, migration of 
leukocytes (neutrophils and macrophages) to the site of injury and by production of growth 
factors and cytokines involved in neo-angiogenesis and cell proliferation (e.g., PDGF, 
VEGF, FGF, TGFβ), and in ECM remodeling proteases (e.g., MMPs, SPARC, Fibronectin), 
thereby promoting wound healing and resolution. In the tumor microenvironment;  
(b) similar factors are produced by tumor-associated macrophages, fibroblasts and cancer 
cells, but neither with temporal control nor in a regulated manner. The continuous 
expression of stimulating growth factors and of proteolytic enzymes leads to a reactive 
milieu and enhanced angiogenesis that support tumor cell survival, proliferation and 
invasion of surrounding tissues. 
 
3. Features of the ECM of Tumors 
In normal tissues resident stromal cells (fibroblasts, leukocytes, endothelial cells) are typically 
quiescent. In tumors, the contrast is macroscopically evident, as observed by pathologists over 100 
years ago. The tumor stroma is highly inhomogeneous with more abundant ECM, activated fibroblasts, 
irregular vessels and numerous inflammatory leukocytes [39-41]. 
In the normal stroma each cell type displays surface receptors appropriate to its environment. ECM 
proteins function cooperatively to modulate the interaction between different cellular components, 
basement membranes and interstitial matrix proteins. These processes keep under strict control various 
cellular processes such as growth, death, adhesion, migration, gene expression and differentiation, and 
are of relevance either to maintain homeostasis and to cope tissue repair in case of injury [4,42]. 
The tumor stroma is characterized by a remarkable subversion of the tissue architecture, especially 
in poorly differentiated carcinoma, and by a different composition of some ECM components. 
Ultrastructural and immunohistochemical analyses revealed the up-regulation of several proteins such 
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as tenascin, decorin, byglican, -smooth muscle actin, osteopontin, fibulin-1, fibronectin, and the 
appearance of spliced protein isoforms that are not normally expressed [4,43-45]. While the vascular 
network in normal tissues is characterized by regular dichotomous branching, the tumor vasculature is 
disorganized, with numerous capillary branches, blind buds or dilated vessels, and a decreased number 
of pericytes. Indeed, neoplastic tissues appear to be in a constant state of tissue damage [43,46-48]. 
Probably the most remarkable characteristic of tumoral stroma is the high level of proteolytic 
degradation [49-51]. This phenomenon has several consequences: first, it alters stroma stiffness and 
removes the physical barriers between cells, facilitating the invasion of migrating cells (neoplastic and 
endothelial cells); second, cleaved ECM proteins may reveal cryptic sites and generate abnormal 
signalling; third, ECM-stored growth factors are released in active form and directly stimulate tumor 
cell survival, proliferation, motility and the neo-angiogenic switch. 
Stromal Signature and Prognosis 
Altered expression of genes related to the ECM has been studied in association with patient clinical 
outcome in a number of human tumors [52-54]. The expression of VEGF and MMP7 predicted the risk 
of poor prognosis in hepatocellular carcinoma [55]. In stomach cancer, the transition from pre-invasive 
to invasive lesions was characterized by the up-regulation of stromal and inflammatory genes. The 
signature associated with adverse clinical outcome included: TGF-related genes (thrombospondin 1); 
metalloproteases (MMP1); junction-mediating and regulatory protein (JMY); markers of stromal 
activation: fibroblast activation protein alpha (Fap-α) [56]. A study in diffuse large-B-cell lymphoma 
revealed two interesting signatures that were more highly expressed in the non-malignant fraction and 
predicted survival in patients. The genes defining the first stromal signature encoded ECM components 
such as fibronectin, Secreted Protein Acidic and Rich in Cysteine (SPARC), various collagen and laminin 
isoforms, modifiers of collagen synthesis and several matrix proteases. The second stromal signature 
encoded endothelial cell-related genes: the von Willebrand factor, CD31, CXCL12 and VEGFR2 [57]. 
Macrophage-related gene signatures have been identified in human tumors such as ovarian and 
breast cancer, soft tissue sarcoma and follicular B lymphoma [57-60]; in classic Hodgkin's lymphoma, 
tumors with increased number of CD68+ TAM were significantly associated with primary treatment 
failure and shortened progression-free survival [61]. 
Further, TAM and related myeloid cells with immune suppressive functions (MDSC) [62-64] and 
the pro-angiogenic Tie-2 monocytes [65] have been implicated in the failure to anti-tumor therapies [66,67] 
via mechanisms that included the secretion of the myeloid cell–dependent angiogenic factor Bv8 [68]. 
4. Matrix Degradation and Remodelling 
Even in normal tissues the ECM is not a static structure and microscopic changes are determined by 
a careful balance between matrix synthesis, secretion, modification and enzymatic degradation. Such 
dynamic remodeling is amplified, in a deregulated manner, in tumor tissues. Matricellular proteins  
are degraded by specific proteases which can be grouped in large families and include matrix 
metalloproteases (MMPs), cathepsins, hyaluronidases, ADAM proteases, but also heparanase, elastase, 
urokinase-type plasminogen activator (uPA), plasmin and others [69,70]. 
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Tumors have high turnover of ECM proteins and protease activity. Although neoplastic cells and 
fibroblasts are able to produce proteolytic enzymes, macrophages are considered the major cell type 
expressing protease activity in tumor tissues [50,71,72]. Immunohistochemical and enzymatic analyses 
in different tumors have shown that increased expression of proteases or changes in cell localization 
are important prognostic factors which correlate with tumor progression [51,73] Proteolysis of ECM 
proteins disrupts integrin-mediated anchorage and focal adhesion kinase (FAK) and is pivotal for 
cancer cell invasion into the adjacent space [31,74-76]. 
TAM and their released factors (e.g., IL-1 and TNF) have long been known to augment tumor 
metastasis [77,78]. In addition they are an important source of proteolytic enzymes, especially MMPs 
and uPA [49,50,79]. Of note, TAM produce several chemokines which beyond regulating cell  
motility–are able to activate MMPs [80,81]. The role of TAM in cancer cell invasion has been 
visualized in experimental tumors in vivo by multiphoton microscopy; by using fluorescently labelled 
cells Wyckoff and colleagues showed that tumor cell intravasation occurs next to perivascular 
macrophages in mammary tumors [82,83]. Further, it has been recently shown that the cathepsin 
protease activity of IL-4-stimulated TAM promotes tumor invasion [84]. IL-4 is produced by  
tumor-infiltrating CD4 T cells and there is mounting evidence of its relevance in the polarization of 
macrophages with pro-tumor functions [85,86]. 
Cleavage of matrix molecules also reveals available binding sites that were previously masked to 
cell surface receptors, and fragments with new functional effects. For instance, MMP-2 degradation of 
collagen unveils integrin-binding sites that rescue melanoma cells from apoptosis [47] while the 
trimeric NC1 domain of collagen XVIII induces angiogenesis [87]. Cryptic epitopes of fibronectin 
trigger angiogenesis and tumor growth [88,89]. 
Over the last decade there has been recognition that proteins of the ECM can modulate multiple 
functions of innate immune cells. A cryptic peptide of laminin-10, a prominent component of 
basement membranes, is chemotactic for neutrophils and macrophages and induces the up-regulation 
of TNF, chemokines and MMP-9 [90]. Particular attention has been given to proteolytic ECM fragments 
and the activation of Toll-like receptors: versican activates TLR2 and TLR6 on TAM and stimulates the 
production of IL-6 and TNF, two prototypic cytokines of cancer-related inflammation [91]. Hyaluronan 
fragments induce the expression of inflammatory genes in immune cells through activation of TLR4 
and TLR2 as well as the CD44 receptor [92]. Thus ECM glycoproteins and glycosaminoglycans can 
directly stimulate inflammatory cells and contribute to fuel inflammation at tumor sites. 
We recently performed an Affymetrix gene profiling of TAM isolated from human ovarian carcinoma 
and found that among the most up-regulated genes were several genes coding for ECM proteins or 
related to its remodelling (Figure 2). Among proteolytic enzymes, the most expressed were MMPs (12, 
9, 1 and 14), Cathepsins (L,C,Z and B), uPA, lysosomal enzymes and ADAM proteases (Figure 2). 
The matrix is a valuable repository of growth factors: members of the EGF and FGF families,  
TGF-beta and related members, as well as PDGF and VEGF, bind to the various components of ECM 
and are stored, in an inactive form, until released and activated by matrix proteases. In the tumor 
context, increased proteolytic activity releases active growth factors which stimulate tumor and 
stromal cells [47,50,93,94]. 
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Figure 2. Gene expression profile of human tumor-associated macrophages. The data refer 
to the expression of genes coding for proteolytic enzymes or ECM proteins. Results are 
mean values from 7 different TAM preparations. Each depicted slice is proportional to the 
expression level of each gene (Affymetrix). 
 
For example, MMPs, plasmin and heparanase degrade the angiogenic factor FGF-beta [95]. MMP-3 
has been shown to cleave the matrix molecule decorin, thereby delivering active TGF-beta [96] and 
MMP13 appears to be essential for the release of VEGF from the ECM in squamous cell  
carcinoma [97]. Of note, during ECM proteolysis fragments with angiostatic activity can also be 
generated. Thus the ultimate biological response really depends on the balance between pro-and  
anti-angiogenic factors. 
Degraded matrix proteins need to be eliminated. A major function of macrophages, dictated by their 
name, is the phagocytosis of apoptotic cells and cellular debris, and their final disposal in specialized 
lysosomal compartments. As mentioned above, TAM expresses high levels of lysosomal-enriched 
cathepsins, which facilitate the elimination of ingested proteins. 
Osteoactivin 
One of the most up-regulated genes in our TAM profiling, as well as in macrophages co-cultured 
with tumor cells [98], codes for the protein osteoactivin, whose function is not completely 
characterized but appears to play a role in tissue repair after injury. Osteoactivin, also called 
glycoprotein non-metastatic melanoma protein B (GPNMB) or haematopoietic growth factor inducible 
neurokinin-1 (HGFIN), was originally identified in osteoblasts/osteoclasts as a critical mediator of 
differentiation, bone remodelling and turnover [99], and in myeloid DC where it negatively regulated 
T cell activation [100]. Studies in tumors showed that it is over-expressed in various malignant tumors 
such as breast cancer, melanoma, glioma, and is involved in the promotion of angiogenesis and tumor 
invasiveness [101,102]. 
A recent report, however, uncovered a novel activity and demonstrated that osteoactivin is essential 
after renal tissue injury for the disposal of cellular debris and appropriate healing [103]. This protein is 
localized on the cell membrane and contains an Arg-Gly-Asp integrin-binding domain, important for 
cell adhesion; upon cleaveage by ADAM10 it is shed into the surrounding milieu [104]. Its role in 
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tissue remodelling and repair was already suggested by the finding that in osteoactivin-transgenic 
mice, it showed a cytoprotective effect on the fibrosis induced by skeletal muscle denervation, via  
a mechanism related to the up-regulation of MMP3 and MMP9 [105]. In ischemic renal injury, 
osteoactivin is up-regulated in damaged epithelial cells, but is much higher in infiltrating macrophages. 
Gpnmb mutant mice had decreased repair of the kidney and macrophages showed many more 
undigested apoptotic cellular debris compared to wild-type mice. In phagosomes, Osteoactivin  
co-localizes with the autophagy protein LC3, and later in lysosomes for final degradation [103]. These 
findings show that osteoactivin is a phagocytic protein produced by macrophages, essential for the 
disposal of injured tissues. 
5. Matrix Deposition by TAM and Their Relationship with Fibroblasts 
Fibroblasts are master regulators of matrix deposition in the stroma and are influenced by stimuli 
coming from both inflammatory cells (macrophages) and neoplastic cells. Several growth factors 
produced by TAM are able to activate fibroblasts: EGF, FGF, PDGF and, above all, TGF-beta. In turn, 
activated fibroblasts (or myofibroblasts, as they start producing a-smooth muscle actin) release growth 
factors for epithelial cells (IGF, EGF, HGF), chemokines for macrophages (CCL2, CXCL12) and 
activated MMPs [28,29,106]. Thus, tumor-associated fibroblasts are key cells of the reactive tumor 
micro-environment. In addition, also TAM are very active producers of matricellular proteins. TAM 
contribute to matrix architecture by producing for instance osteopontin, fibronectin, proteoglycans, 
SPARC and different collagen types [14,15,107]. 
5.1. Osteopontin 
Several ECM-related genes were expressed in our gene-profiling from human TAM (Figure 2). The 
top expressed gene was osteopontin; this protein is a component of the ECM being a secreted protein 
and is produced also by stromal and tumor cells [108-110]. Osteopontin has multiple functions in 
tumors being involved in protease activation and ECM remodelling, cell adhesion and migration, 
angiogenesis, as well as in inflammation and immunity [107,111-114]. Serum levels of osteopontin are 
elevated in cancer patients and usually correlate with tumor progression, raising the issue of its clinical 
use as a potential biomarker [108,115,116]. 
The involvement of this ECM protein has been demonstrated in several aspects of malignancy. A 
correlation between osteopontin up-regulation and malignant invasion was suspected because this protein 
controls cell motility and invasion through the engagement of CD44 receptors and integrins [110,117].  
It was also involved in the accelerated proliferation of indolent tumors, via the pro-tumoral role  
of bone marrow-derived leukocytes, that are recruited by Osteopontin and activated to produce 
inflammatory cytokines [118]. A pro-migratory effect has been demonstrated also on endothelial cells. 
Osteopontin-mediated matrix degradation, achieved by the activation of MMP9 and uPA, indirectly 
promotes the neo-angiogenic switch [111,112,119,120]. Therefore, cell-ECM adhesion, inhibition of 
apoptosis and induction of migration are crucial functions mediated by osteopontin that eventually 
promote tumor cell survival and dissemination. 
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5.2. Migration Stimulation Factor 
Among the classical ECM proteins that we found up-regulated in TAM and in tumor-conditioned 
macrophages was fibronectin [98]. Spliced isoforms of fibronectin, also called oncofoetal isoforms 
ED-A and ED-B, are known to be increased in tumors and during embryogenesis [121-124]. A  
number of studies have reported their role in promoting endothelial cell migration and tumor 
angiogenesis [43,123,124]. We found that tumor macrophages expressed a third oncofetal FN isoform, 
known as Migration Stimulation Factor (MSF) [98]. MSF is a truncated isoform of fibronectin 
identical to the 70-kDa N terminus but with a unique 10 aa sequence. MSF was cloned in 2003 by 
Schor and colleagues who demonstrated its potent motogenic activity on fibroblasts [125]. Of interest, 
Macrophage-secreted MSF potently stimulated the in vitro migration of tumor cells, as well as 
monocytes [98]. This truncated fibronectin isoform is not an exclusive product of TAM, being 
produced also by neoplastic cells and vascular endothelial cells [125,126]. Of note, MSF is expressed 
in vitro only by M2 macrophages and is down-regulated in M1 cells. Thus, MSF may represent a good 
candidate marker of the M2-type polarization of TAM. 
5.3. SPARC 
SPARC is another matricellular glycoprotein highly expressed at sites of tissue remodelling. 
SPARC regulates the interactions between cells and their microenvironment, mediating matrix 
deposition and turnover, cell adhesion and signaling by extracellular factors. In neoplastic tissues, 
SPARC is expressed in the stroma and in malignant cells of some types, and affects tumor 
development, metastasis, angiogenesis and inflammation. SPARC-induced changes can suppress or 
promote progression of different cancers depending on the tissue and cell type. In some cancers, such 
as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in 
others, mainly ovarian cancer, neuroblastoma and colorectal cancer, SPARC may function as a tumor 
suppressor [127-129]. 
A major function of SPARC is its involvement in collagen deposition, as demonstrated in tumors 
transplanted in Sparc-/- mice: growing tumors showed reduced collagen fibers and decorin deposition. 
In addition SPARC binds to other components of the ECM and of the basement membranes, such as 
entactin/nidogen and thrombospondin 1, and therefore contributes to the organization of the interstitial 
matrix. Probably because of this altered matrix, pancreatic tumors grown orthotopically in Sparc-/- 
mice were more metastatic than tumors grown in wild-type mice [130,131]. 
The relationship of SPARC and the immune system has also been studied in tumors. In  
tumor-bearing Sparc-/- mice there was a reduced macrophage recruitment suggesting that SPARC may 
have chemotactic activity on macrophages [132,133]. Of interest, TAM and M2-polarized 
macrophages express the SPARC receptor, Stabilin-1, a scavenger receptor that targets SPARC for 
lysosomal degradation [134]. Thus a reciprocal feedback control is envisaged: SPARC recruits 
macrophages which, in turn, express stabilin-1 that clear SPARC from the environment.  
Another SPARC-related loop, interconnecting tumor biology and immunity, was demonstrated by 
Sangaletti et al. They analyzed the respective roles of host- and tumor-derived SPARC in wild-type 
and SPARC-/- mice using bone marrow chimeras. It turned out that SPARC produced by infiltrating 
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leukocytes, rather than by the tumor, was instrumental in appropriate deposition of collagen IV in 
peritumoral stroma from mammary carcinoma, whereas reciprocal chimeras (SPARC-/- bone marrow 
cells in wild type mice) developed tumors with less defined lobular structures [135]. The data underlie 
the importance of SPARC (produced by host leukocytes) in the assembly and organization of tumor 
stroma. Further, the same group showed that SPARC produced by TAM enhances cancer cell 
migration and spontaneous metastasis, via a mechanism that involved avb5 integrin [136]. 
6. Targeting of TAM in Tumors 
As summarized above, TAM functional activities importantly contribute to the construction of the 
reactive tumor micro-environment and are, therefore, amenable targets of biological therapies. 
Macrophage depletion in experimental settings has been successful in decreasing tumor growth and 
metastatic spread [11,137,138]; furthermore their depletion may contribute to a better response to 
conventional chemotherapy and anti-angiogenic therapy [62,63,65-67]. Several approaches have been 
followed to target TAM in tumors such as inhibition of their recruitment at tumor sites or the use of 
cytotoxic drugs, for example, biphosponates. 
A number of studies have shown that the bisphosphonate clodronate-encapsulated in liposomes is 
an efficient reagent for the depletion of macrophages. Clodronate-depletion of TAM in tumor-bearing 
mice resulted in reduced angiogenesis and decreased tumor growth and metastasis [139]. Moreover, 
the combination of clodronate with sorafenib significantly increased the efficacy of sorafenib alone in 
a xenograft model of hepatocellular carcinoma. In clinical practice, bisphosphonates are employed to 
treat osteoporosis; current applications in cancer treatment include their use to treat skeletal metastases 
in multiple myeloma, prostate and breast cancer. Treatment with zoledronic acid was associated with  
a significant reduction of skeletal-related events and, possibly, direct apoptotic effects in tumor  
cells [140-142]. 
Another approach is to inhibit the recruitment of circulating monocytes in tumor tissues. Among the 
many chemokines expressed in the tumor micro-environment, CCL2 (or monocyte chemotactic 
protein-1) occupies a prominent role and has been selected for therapeutic purposes. Pre-clinical 
studies have shown that anti-CCL2 antibodies or antagonists to its receptor CCR2, given in 
combination with chemotherapy, were able to induce tumor regression and yielded to improved 
survival in prostate mouse cancer models [143-145]. 
A third and more recent approach is to ‘re-educate’ TAM to exert anti-tumor responses protective 
for the host, ideally by using factors able to switch the M2-phenotype of TAM into that of  
M1-macrophages with potential anti-tumor activity. This was achieved in experimental mouse tumors 
by injecting the TLR9 agonist CpG- oligodeoxynucleotide (CpG-ODN), coupled with anti-IL-10 
receptor [146] or the chemokine CCL16 [147]. CpG-ODN synergized also with an agonist anti-CD40 
mAb to revert TAM displaying anti-tumor activity [148]. A remarkable anti-tumor effect of re-directed 
macrophages has been recently reported in human pancreatic cancer with the use of agonist anti-CD40 
mAb [149]. A recent report showed that the plasma protein histidine-rich glycoprotein (HRG), known 
for its inhibitory effects on angiogenesis [150,151] is able to skew TAM polarization into M1-like 
phenotype by down-regulation of placental growth factor (PlGF), a member of the VEGF family. In 
mice, HRG promoted anti-tumor immune responses and normalization of the vessel network [152]. 
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The intense protease activity present within tumors has been the object, over several years, of 
pharmaceutical research, looking for specific MMPs inhibitors [49,50]. The first generation of 
developed compounds were competitive inhibitors (e.g., batimastat), and later were derivatives of 
tetracycline, which inhibited MMP gene transcription and enzymatic activity. Of note, also the 
biphosponates inhibit MMP activity. When tested in clinical trials several years ago, these compounds 
gave overall disappointing results. The field, however, is still active and considering the use of 
monoclonal antibodies specific for membrane-bound MMPs, such as MMP14 [51,153]. 
Few years ago, by studying a new anti-tumor agent of marine origin, trabectedin, we unexpectedly 
observed that this compound was highly cytotoxic to monocytes and macrophages, with a remarkable 
selectivity, as neutrophils and lymphocytes were not killed [154]. Trabectedin has now been registered 
in 2007 in Europe for the treatment of soft tissue sarcoma, and in 2009 for ovarian cancer [155-157]. 
Trabectedin also affects gene transcription with a peculiar selectivity; some inflammatory cytokines 
and chemokines are reduced by the drug, such as IL-6, CCL2, CXCL8, VEGF, while TNF is not 
inhibited [158]. Another affected gene is collagen [159]. We therefore tested whether other  
ECM-related genes produced by macrophages were reduced by the drug. In in vitro experiments with 
monocytes/macrophages we found that low non-cytotoxic concentrations of trabectedin significantly 
decreased the expression of both the full length fibronectin and MSF. Also osteopontin and MMP2 
were inhibited, while osteoactivin was not (Liguori, unpublished data). These results indicate that 
trabectedin may reduce the high turnover of the tumor stroma. This effect of “normalization” of the 
micro-environment, combined with its cytotoxic effect on macrophages and tumor cells, makes 
trabectedin an interesting compound in oncology. 
7. Conclusions 
In the last decades the concept that the ECM is simply a supporting structure for the preservation of 
tissue architecture has dramatically changed [160]. Indeed, ECM components provide signals affecting 
cell adhesion, migration, proliferation and differentiation. In particular, degraded/proteolytic fragments 
of ECM molecules or their aberrant expression, as occurs during neoplastic transformation, can sustain 
the activation of inflammatory cells. TAM are key players of the cancer-related inflammation present 
at tumor sites. In addition to releasing cytokines and growth factors, a distinguished feature of TAM is 
their high rate of remodelling of the tumor stroma, in which they vigorously participate by expressing 
proteolytic enzymes and ECM proteins, some of which are specific to the neoplastic tissues. Such  
a reactive micro-environment eventually supports tumor cell proliferation and the full-blown 
development of neo-angiogenesis. There is increasing evidence that successful anti-cancer therapies are 
not only dependent on the cancer phenotype but also on the normalization of the tumor stroma. In this 
view, depletion of the unfaithful TAM, or their “re-education”, may contribute to the success of 
conventional anti-tumor therapies. 
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